SPECTRUM PHARMACEUTICALS, INC. (NASDAQ:SPPI) Files An 8-K Results of Operations and Financial Condition

SPECTRUM PHARMACEUTICALS, INC. (NASDAQ:SPPI) Files An 8-K Results of Operations and Financial Condition
Item 2.02Results of Operations and Financial Condition.

Story continues below

On August3, 2017, Spectrum Pharmaceuticals, Inc. issued a press release, which, among other matters, sets forth our results of operations for the quarter ended June30, 2017. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

The foregoing information, including Exhibit 99.1, is being furnished under Item 2.02 and shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.

Item 2.02Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.

Description

99.1

Press Release dated August 3, 2017


SPECTRUM PHARMACEUTICALS INC Exhibit
EX-99.1 2 exhibit9916302017.htm EXHIBIT 99.1 Exhibit COMPANY CONTACTSShiv KapoorVice President,…
To view the full exhibit click here

About SPECTRUM PHARMACEUTICALS, INC. (NASDAQ:SPPI)

Spectrum Pharmaceuticals, Inc. is a biotechnology company. The Company operates through developing and commercializing oncology and hematology drug products segment. It has approximately six approved oncology/hematology products that target different types of non-Hodgkin’s lymphoma (NHL), metastatic colorectal cancer, acute lymphoblastic leukemia (ALL) and multiple myeloma (MM). It also has two drugs in late-stage development: SPI-2012, which is being developed for chemotherapy-induced neutropenia in patients with breast cancer, and EOQUIN, which is being developed for immediate intravesical instillation post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer. It has a product portfolio consisting of both commercial-stage and development-stage products that address various cancer types. Its commercialized products include FUSILEV, FOLOTYN, ZEVALIN, MARQIBO, BELEODAQ and EVOMELA. Its other products include SPI-2012, POZIOTINIB and EOQUIN.

An ad to help with our costs